Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee
Summary of Main Points from the Meeting held on the 9th June 2014

2. Minutes and Summary Notes from last meeting
The Minutes and Summary notes from the May 2014 meeting were approved and will be circulated.

3. Matters Arising
The Committee noted the matters arising from the previous meeting.

4. Formulary Applications
Full applications

- **Tolvaptan 15mg and 30mg Tablets (Samsca®)**

Decision: Approved
Indicated for the third line treatment of adult patients with hyponatraemia secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH). This is currently being funded by NHS England providing it is used within the product license.

- **Sofosbuvir 400mg Tablet (Sovaldi®)**

Decision: Approved
Indicated in combination with (Ledispavir and Daclastavir +/- Ribavirin) for the treatment of chronic Hepatitis C Virus in adults. On account of early favourable results from clinical trials, NHS England has allocated funding for the use of Sofosbuvir to treat 500 patients nationally. Ledispavir and Daclastavir will be provided to these patients as part of the combination therapy regimen on a compassionate basis. Strict criteria will be exercised for patient selection and the decision to treat will be made by a regional multi-disciplinary panel (MDT). A submission has been made for C&W to join the Imperial Healthcare MDT. It is likely that the issue of Sofosbuvir will need to be reconsidered by the Medicines Committee Panel once the 500 patient allocation has been exhausted.

Ex-Panel requests

- **Ganfort® (Bimatoprost & Timolol) Unit Dose Vials**

Decision: Approved
UDV formulation - Drops currently on the formulary.
Preservative free formulation
Favourable price negotiated with the manufacturer.
Included on NWLIF.

- **Xailin Night® Eye Ointment**

Decision: Approved
To replace Lacrilube® eye ointment.
£1.78 as opposed to £2.64 per tube.
Trust saving: £1,020 per annum.
Approved for use in primary care at the NWLIF panel meeting on 5th June.

- **Memantine 10mg/ml Liquid**

Decision: Approved
Liquid formulation.
Tablets currently on the formulary.
Ensure compliance for patients unable to swallow solid dosage forms.

- **Donepezil 5mg and 10mg Orodispersible Tablets**

Decision: Approved
Orodispersible tablet formulation
Tablets currently on the formulary.
Ensure compliance for patients unable to swallow solid dosage forms.

- **Hyaluronic acid (Ostenil Plus®) Injection**

Decision: Approved
Durolane® currently on the formulary.
£96 as opposed to £176 per injection.
Trust saving: £62,000 (Currently all claimed back from CCG but this may change in the future).

- **Fomepizole 5mg/ml or 1g/ml Injection**

Decision: Approved
As an antidote for Ethylene Glycol and Methanol overdose as detailed in the finalised Emergency Department Antidote Location guideline. On account of Fomepizole being added to formulary the Emergency Department Antidote Location Guideline is now approved.

Application form for noting

- **Afatinib 20mg, 30mg, 40mg and 50mg Tablets (Giotrif®)**

Decision: Noted (Approved in May 2014)

Feedback from NWLIF Panel meeting - 5th June
Three submissions were made by C&W:

- **Fluticasone / Vilanterol via Ellipta® inhaler (Relvar®) (Full submission)**

Not approved due to safety concerns relating to the colour of the device.

- **Solifenacin 6mg & Tamulosin 400mcg Tablet (Vesomni®) (Full submission)**

Not approved due to the preferred second choice agent in Primary Care being Tolterodine and not Solifenacin.

- **Xailin Night® Eye Ointment (Ex-panel)**

Approved

5. MHRA/NHS England Patient Safety Alerts

- **Minimising risks of omitted and delayed medicines for patients receiving homecare services (2014/007)**

Decision: Approved

All actions now completed and action plan approved and signed off. The action plan will be forwarded to the Trust Risk Management Committee for noting.

- **Non-Luer spinal (Intrathecal) devices for chemotherapy (2014/002)**

Decision: Approved

All actions now completed and action plan approved and signed off. The action plan will be forwarded to the Trust Risk Management Committee for noting.

6. Trust Medicines Policy

- **TMP Section: 6 Controlled Drugs**

Decision: Approved

Updated in line with legislative changes in the classification of Tramadol, Lisdexamfetamine and Zopiclone which comes into force on 10th June 2014.

- **TMP Section: 20 Unlicensed use of a licensed medicine**

Decision: Approved

Scheduled review and update - Minor changes

- **TMP Section: 23 Methotrexate for non-cancer indications**

Decision: Approved

Scheduled review and update - Minor changes

7. Medicines Management

- **Single checking of IV drug administration in Pharmacological Stress Testing - Risk Assessment**

Decision: Noted

Risk assessment relating to single checking of IV drug administration in Pharmacological Stress Testing. The general consensus from discussion was that there is a need to exhaust all possibilities of introducing a second check from another healthcare professional who works in the vicinity of the clinic.

- **Morphine sulphate PCA syringe to vial switch - Proposal and Risk Assessment**

Decision: Deferred for further consideration

Proposal and risk assessment relating to switching from morphine sulphate PCA syringe (Unlicensed special) to vial (Licensed commercial product). This was deferred as further consideration was required to assess the effect this change will have on nursing time, safety and the risk of misappropriation

- **Paediatric Emergency Department medication infusion chart**

Decision: Approved with suggested amendments

Newly compiled medication infusion chart for use in the Paediatric Emergency Department. This aims to capture all details relating to the infusion including staff signatures etc. A number of amendments were suggested. In principal approval was granted providing suggested amendments are incorporated.

8. NICE TA Guidance

TA312 - Alemtuzumab for treating relapsing-remitting multiple sclerosis Alemtuzumab is recommended as an option, within its marketing authorisation, for treating adults with active relapsing - remitting multiple sclerosis.

Action: Added to the formulary pending completed application form from the Neurology Team

TA313 - Ustekinumab for treating active psoriatic arthritis

Ustekinumab is not recommended within its marketing authorisation for treating active psoriatic arthritis, that is, alone or in combination with methotrexate in adults when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate.

Action: Nil - Not recommended

9. IVIG Update

The panel noted the IVIG report.

There were 9 IVIG issues in May 2014, with 3 new requests:

- One for Toxic Epidermal Necrolysis (TENS) (Red indication)
- One for Necrotising (PVL-associated) Staphylococcal Sepsis (Blue Indication)

- One for Paraneoplastic Disorder that is known not be B or T Cell mediated (Grey indication) (Approved by the PE Board).

10. Items for noting

- **High Cost Drugs excluded from DH Tariff - 2014-15**

High cost drugs excluded from DH tariff for 2014-15. This is now available on the Trust intranet.

- **Safe secure storage of medicines audit - March 2014 (On-site**

Safe secure storage of medicines audit (On-site) report undertaken in March 2014.

- **PGD Tracker - June 2014**

PGD Tracker for June 2014.

- **Drugs Sub-Committee meeting minutes - April 2014**

Drugs Sub-Committee meeting minutes for April 2014

- **Drugs Sub-Committee meeting minutes - May 2014**

Drugs Sub-Committee meeting minutes for May 2014

13. Date of next meeting

Monday 14th July 2014, 8.00 - 9.00 – Board Room, Lower Ground Floor
Closing date for papers: Friday 20th June 2014